FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a nucleic acid encoding a chimeric receptor specifically bound to CD19. Nucleic acid contains a polynucleotide coding a ligand-binding domain, a polynucleotide coding the transmembrane domain, a polynucleotide coding a polypeptide spacer between the ligand-binding and transmembrane domains, and a polynucleotide coding the intracellular signal domain. Polypeptide spacer has length of 15 amino acids or less and contains amino acid sequence X1PPX2P, where X1 is cysteine, glycine or arginine, and X2 is cysteine or threonine. Also disclosed are polypeptide chimeric receptors, expression vectors, host cells, methods and compositions for providing and/or amplifying immune responses mediated by cell immunotherapy, for example, by adoptive transfer of central CD8 + memory T-cells or combinations of central memory T-cells and T- CD4 + cells genetically modified for chimeric receptor expression.
EFFECT: invention provides higher survival and in vivo efficacy of T-cells modified with a chimeric receptor, and can be used for cancer therapy.
55 cl, 20 dwg, 24 tbl, 3 ex
